Plain English Summary
Background and study aims
Lateral Compression (type 1) fractures of the pelvis make up around 60% of pelvic fractures. A proportion of these are termed as unstable, meaning that there is a greater risk of the bone fragments displacing over time. This may lead to difficulties with mobilising and prolonged periods of pain. Therefore it may be appropriate to stabilise these fractures through surgery. However, surgery also has some significant risks such as infection, nerve damage etc. Currently there is no evidence to support either surgical or non-surgical management of these fractures. This study aims to test the feasibility of carrying out a future large scale study to inform the most appropriate management of these injuries.
Who can participate?
Patients aged 16 and older with an LC1 fracture with complete sacral fracture
What does the study involve?
Participants are randomly allocated to either follow a surgical or a non-surgical treatment pathway. The exact details of these two pathways are left to the discretion of each patient’s treating pelvic specialist. Participants are assessed at regular intervals to complete questionnaires relating to their symptoms and daily activities as well as a physical assessment of their walking. A small proportion of participants are asked to take part in an interview to examine their acceptance of the treatments, study design and assessments used. The number of patients recruited to the study and the completeness of the data are also assessed.
What are the possible benefits and risks of participating?
Participation in this study will help us to design a future study to inform the most appropriate treatment of patients with an unstable LC1 fracture in the future. It is hoped that the outcomes of this future study will provide clearer information on whether surgical treatment of these injuries is most appropriate.
Where is the study run from?
1. Southmead Hospital (UK)
2. John Radcliffe Hospital (UK)
3. University Hospital Coventry and Warwickshire (UK)
4. Royal London Hospital (UK)
5. St George’s Hospital (UK)
When is the study starting and how long is it expected to run for?
April 2018 to December 2020
Who is funding the study?
National Institute for Health Research (NIHR) (UK)
Who is the main contact?
Mr Steven Barnfield
TULIPStudy@nbt.nhs.uk
Trial website
Contact information
Type
Scientific
Primary contact
Mr Steven Barnfield
ORCID ID
Contact details
North Bristol NHS Trust
Southmead Hospital
Westbury-on-Trym
Bristol
BS10 5NB
United Kingdom
+44 (0)117 4141690
TULIPStudy@nbt.nhs.uk
Additional identifiers
EudraCT number
ClinicalTrials.gov number
Protocol/serial number
38613
Study information
Scientific title
A randomised controlled trial of surgical versus non-surgical treatment of lateral compression injuries of the pelvis with complete sacral fractures (LC1) in the non-fragility fracture patient - a feasibility study
Acronym
TULIP
Study hypothesis
Lateral Compression (type 1) fractures of the pelvis make up around 60% of pelvic fractures. A proportion of these are termed as unstable meaning that there is a greater risk of the bone fragments displacing over time. This may lead to difficulties with mobilising and prolonged periods of pain. Therefore it may be appropriate to stabilise these fractures through surgery. However, surgery also has some significant risks such as infection, nerve damage etc. Currently there is no evidence to support either surgical or non-surgical management of these fractures. This study aims to test the feasibility of carrying out a future large scale study to inform the most appropriate management of these injuries.
Ethics approval
South West – Central Bristol Research Ethics Committee, 02/07/2018, ref: 18/SW/0135
Study design
Randomised; Interventional; Design type: Treatment, Surgery
Primary study design
Interventional
Secondary study design
Randomised controlled trial
Trial setting
Hospitals
Trial type
Treatment
Patient information sheet
Not available in web format, please use the contact details to request a patient information sheet
Condition
Pelvis fracture
Intervention
Patients with a pelvic fracture will be referred to one of the hospitals specialising in the treatment of these injuries. Those identified as having sustained an unstable LC1 fracture by their treating pelvic specialist, and meeting the criteria for inclusion in the study, will be approached to see if they would be willing to take part in the study. Patients will be asked to complete a written consent form to indicate their agreement to take part and will be asked to complete a series of short questionnaires relating to their daily activities and symptoms both prior to and since their injury. They will then be randomised by computer to follow either a non-surgical or surgical pathway.
Patients assigned to a non-surgical pathway will be allowed to mobilise according to the advice of their pelvic specialist and with the guidance of a physiotherapist using appropriate walking aids. This may involve a period where they are restricted from putting their full bodyweight through their pelvis. Patients will be reviewed by their pelvic specialist at 2 weeks following their injury, as per normal practice, to monitor for any movement in their fracture.
Patients assigned to surgical management of their fracture will have surgery to stabilise the broken bones, using metalwork to fix the pelvis, performed at the earliest opportunity by a specialist pelvic surgeon. Following the surgery they will be able to mobilise as guided by their surgeon and a physiotherapist. This may involve a period where they are restricted from putting their full bodyweight through their pelvis.
Follow-up of patients as part of the study will take place at 2 & 6 weeks, 3, 6, 9 and 12 months following randomisation. At all these time points they will be asked to complete the same series of questionnaires relating to their symptoms and daily activities completed when they initially agreed to take part in the study. Additionally patients will be asked to provide a few details on the rehabilitation they have received and any healthcare resources used (e.g. physiotherapy, GP visits etc) during their treatment.
These questionnaires will be posted to patients at all time points. If no response is received then they may be completed by telephone with a member of the research team at the site at which they were recruited. Alternatively, at 6 weeks, 3 and 12 months, they may be completed with patients during their normal clinical review. At 6 weeks, 3 and 12 months, when patients are being reviewed by their pelvic specialist as part of their usual care, they will also be asked to complete a simple test of their walking ability with an independent assessor who is unaware of the treatment they have received.
A small group of participants will be asked if they are willing to take part in a short interview to assess the acceptability of the study design, including the recruitment process, treatments and follow-up procedures. A group of staff involved in the recruitment and treatment of patients will also be invited to take part in a short interview to assess their views of the study treatments and study design. These interviews will help to inform the design of the future larger scale study.
Intervention type
Procedure/Surgery
Phase
Drug names
Primary outcome measure
The aim of this research study is to perform a feasibility study which will allow the researchers to plan a full definitive trial. A future trial will be deemed to be feasible if the overall recruitment rate is greater than 40% of potential participants per centre per month.
The objectives of this feasibility study are;
1. To produce a CONSORT (consolidated standards of reporting trials) diagram, reporting screening, recruitment, randomisation compliance and include allocation proportions by centre
2. To confirm the recruitment rates and percentage of eligible patients who agree to take part
3. To collect outcome data at 2 & 6 weeks, 3, 6, 9 & 12 months post injury to collate the completeness and spread of the data at different time points post injury
4. To identify the outcome measure to be used as the primary outcome on the basis of completeness of data, sensitivity to change over time, the presence of floor or ceiling effects and patient acceptability
5. To develop and refine methods for the collection of resource use data relating to both management pathways
6. To explore patient and staff views of randomisation, treatment and trial processes using qualitative interviews
Secondary outcome measures
The outcome measures being assessed in this feasibility study for use in a future definitive trial are;
1. Iowa pelvic score – a measure specific to outcomes after pelvic injury
2. Oxford Hip score – a functional score for patients after hip/pelvic injury
3. EQ-5D-5L – a generic quality of life score
4. ICECAP-A – a measure of capability for the general adult population for use in economic evaluation
5. Brief Pain Inventory – a measure of pain severity and its effect on the patient
All the above outcomes will be assessed at 2 and 6 weeks, 3, 6, 9 and 12 months to assess the most appropriate timepoints to be chosen for a future definitive trial.
In addition the patients functional ability will be measured using the Timed Up and Go assessment carried out by a blinded assessor at 6 week, 3 months and 12 months.
Overall trial start date
01/04/2018
Overall trial end date
31/12/2020
Reason abandoned (if study stopped)
Eligibility
Participant inclusion criteria
1. LC1 fracture with complete sacral fracture
2. 16 years and older
Participant type
Patient
Age group
Adult
Gender
Both
Target number of participants
Planned Sample Size: 60; UK Sample Size: 60
Total final enrolment
37
Participant exclusion criteria
Current participant exclusion criteria as of 06/08/2019:
1. Unable to be randomised within 72 hours of having capacity to comprehend the study information following arrival at the major trauma centre
2. Fragility fractures resulting from low-energy trauma (fall from less than standing height)
3. Presenting medical condition which precludes surgical intervention
4. Unable to provide informed consent
Previous participant exclusion criteria:
1. No bony anterior pelvic ring injury
2. Unable to be randomised within 2 weeks of injury
3. Unable to mobilise for 6 metres prior to injury
4. Fragility fractures resulting from low-energy trauma (fall from less than standing height)
5. Unfit for anaesthesia
6. Unable to provide informed consent
7. Unable to adhere to Protocol
Recruitment start date
09/07/2018
Recruitment end date
31/03/2020
Locations
Countries of recruitment
United Kingdom
Trial participating centre
Southmead Hospital
Southmead Road
Bristol
BS10 5NB
United Kingdom
Trial participating centre
John Radcliffe Hospital
Headley Way
Oxford
OX3 9DU
United Kingdom
Trial participating centre
University Hospital Coventry and Warwickshire
Clifford Bridge Road
Coventry
CV2 2DX
United Kingdom
Trial participating centre
Royal London Hospital
Whitechapel Road
London
E1 1BB
United Kingdom
Trial participating centre
St George's Hospital
Blackshaw Road
London
SW17 0QT
United Kingdom
Sponsor information
Organisation
North Bristol NHS Trust
Sponsor details
Southmead Hospital
Southmead Road
Westbury-On-Trym
Bristol
BS10 5NB
United Kingdom
+44 (0)117 4149330
Researchsponsor@nbt.nhs.uk
Sponsor type
Hospital/treatment centre
Website
Funders
Funder type
Government
Funder name
NIHR Central Commissioning Facility (CCF); Grant Codes: PB-PG-0816-20013
Alternative name(s)
Funding Body Type
Funding Body Subtype
Location
Results and Publications
Publication and dissemination plan
The aim is to present the results from this feasibility study locally at each recruitment site, nationally at the Orthopaedic Trauma Society Annual meeting and also at the British Orthopaedic Association annual meeting to the general orthopaedic community. The results will be submitted for publication as an original article in a peer reviewed open access journal, possibly the BJJ (Bone & Joint Journal) or the JOT (Journal of Orthopaedics and Trauma). It is anticipated that potential publications will discuss the methodology of the study, including the outcome measures used and their ease of use by patients. As well as this it is hoped that the study will show the timepoint in patients recovery from these injuries where changes in their outcome are most significant and therefore the timepoint at which any primary outcome should be assessed. The study should also be able to provide some insight into patients views on the two treatment options and their willingness to be randomised to these treatments.
IPD sharing statement
The anonymised, full trial dataset will be stored on a REDCap database located on the University of Bristol servers. Access to the final trial dataset will only be available to members of the Trial Management Group (TMG) and Statistician. Individual sites will be given access to the dataset for their own recruited patients only. This will be made available following the final publication and on receipt of a written request to the TMG. Requests for other study documents will be considered by the TMG and should be made in writing to the contact details above.
Intention to publish date
31/12/2021
Participant level data
Stored in repository
Basic results (scientific)
Publication list
2020 protocol in https://www.ncbi.nlm.nih.gov/pubmed/32047021 (added 13/02/2020)